AveragePenny
4 days ago
$USAQ QHSLab, Inc. (OTCQB: USAQ) Marks Major Achievements in Digital Health Innovation, Research Recognition, and Revenue Growth in 2024
https://www.globenewswire.com/news-release/2024/11/25/2986675/0/en/QHSLab-Inc-OTCQB-USAQ-Marks-Major-Achievements-in-Digital-Health-Innovation-Research-Recognition-and-Revenue-Growth-in-2024.html
Revenue Growth and APA Recognition Drive Momentum for QHSLab in 2024
WEST PALM BEACH, FL, Nov. 25, 2024 (GLOBE NEWSWIRE) -- QHSLab Inc. ("the Company") (OTCQB: USAQ), an emerging leader in digital healthcare solutions and value-based clinical technologies, today proudly announces significant milestones that underscore its progress in 2024. These accomplishments demonstrate the Company’s commitment to advancing patient care, driving innovation, and delivering value to shareholders.
QHSLab Research & Development: Advancing Mental Health Innovation
QHSLab is thrilled to share that two research abstracts, developed in collaboration with the Southern Winds Hospital Psychiatry Residency Program, have been accepted for presentation at the 2025 Annual Meeting of the American Psychiatric Association (APA) in Los Angeles, CA.
This recognition highlights QHSLab’s innovative approach to managing depression, anxiety, and chronic pain through its digital health journeys. Preliminary findings reveal reductions in symptom severity and improvements in quality of life for participants. These results affirm the transformative potential of QHSLab’s interventions in real-world clinical settings, showcasing its role at the forefront of mental health care innovation.
Marcos Sanchez-Gonzalez, MD, PhD. VP of Medical and Scientific Affairs, remarked:
"The APA acceptance and our ongoing clinical research exemplify how digital medicine can revolutionize chronic condition management in primary care settings. These efforts not only advance our understanding of health solutions but also significantly improve patients’ lives."
Milestone Two Achieved in the Digital Medicine for Allergic Rhinitis (DMAR) Study
Supported by a grant from a global leader in consumer health, QHSLab’s collaborative study on allergic rhinitis has reached its second milestone. Recruitment for the first round of participants surpassed initial projections, bringing the study closer to its goal of evaluating the impact of digital tools on symptom control, medication adherence, and quality of life.
This progress reflects QHSLab’s ability to execute large-scale clinical research initiatives effectively, positioning its digital platform as a transformative tool in allergy management.
October 2024 Sales Performance: Demonstrating Strong Growth
Unaudited sales for October 2024 reached approximately $225,000, representing a 110% increase compared to the same period in 2023. This robust growth highlights the scalability and market acceptance of QHSLab’s solutions.
On an annualized basis, the current monthly run rate equates to annual revenues of $2.7 million, emphasizing the success of the Company’s strategic initiatives. While the reported revenues for October are unaudited, management is confident the results will be confirmed. This illustrates the momentum QHSLab is building as it continues to expand its offerings.
Executive Commentary
Troy Grogan, CEO of QHSLab, commented:
"The recognition by the APA and our exceptional sales growth this year are clear indicators of the strength of our vision and execution. Our unwavering commitment to innovation in digital health enables us to deliver impactful solutions that enhance patient outcomes while creating value for shareholders."
Dr. Sanchez-Gonzalez added:
"These achievements reinforce the efficacy of QHSLab’s solutions and their potential to address critical challenges in healthcare. Through our research and product innovation, we are charting a course to revolutionize care in both mental health and chronic conditions."
For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.
Captainandy
2 years ago
#USAQ: QHSLab, Inc. Launches a “Long COVID” Digital Health Tool for Primary Care Physicians...
https://www.usaqcorp.com/
https://finance.yahoo.com/news/qhslab-inc-launches-long-covid-123000685.html
Primary care physicians now have access to reimbursable digital tools for the routine assessment of post-COVID conditions
Strengthening QHSLab’s Business Model and Expanding Digital Health Product Portfolio in the Large Primary Care Market
Long COVID Digital Health Tool Focused on Primary Care Represents a Compelling and Reimbursable Value Proposition for QHSLab’s Physician Clients
1 in 5 Adults has a New Health Condition that Might be Related to a Previous COVID-19 Infection
WEST PALM BEACH, FL, Sept. 20, 2022 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point of care technologies, today announced the launch of its proprietary Post-COVID Condition Health Habits digital health tool for screening primary care patients potentially suffering from a “long COVID” or “post-COVID” conditions.
The CDC estimates that 1 in 5 adults over the age of 18 has a health condition that might be related to having had a COVID infection in the past. Currently labeled as a “long COVID” or “post-COVID” condition, defined as having symptoms persisting after or beginning approximately four weeks after first contracting the virus and lasting three or more months after the acute infection, that a patient did not have prior to their COVID-19 infection.
Primary care physicians (PCPs) are usually the first contact for patients suffering from long COVID conditions, and medical researchers are yet to catch up and provide much-needed guidelines for the management of patients complaining of symptoms relating to long COVID conditions. PCPs measure their patient's health status to form baselines to enable future monitoring of conditions and the effects of treatments. Until now, there have been few easy-to-use, quick, and reimbursable tools to measure a patient's potential long COVID health and functional status and provide the PCP with clinical decision-making support relating to their patient’s health habits and lifestyle that may improve a patient's functional status and reduce the risk of future chronic diseases such as heart disease, diabetes, respiratory conditions and mental health, for example.
The latest QHSLab digital health tool has been developed to quickly assess functional status and recovery from COVID-19 and aims to provide PCPs with baseline data relating to measuring long COVID symptoms, including, but not limited to, shortness of breath, pain, fatigue, muscle weakness, memory loss, depression, and anxiety as well as a range of functional limitations, such as changes in lifestyle, work, sports, and social activities.
“This much-needed reimbursable long COVID digital health tool will assist PCPs to initially measure and also track progress over time and has the potential to answer some meaningful clinical questions for long-term research into this new healthcare phenomenon,” said Troy Grogan, President and CEO of QHSLab, Inc.
The Post-COVID-19 Health Habits Assessment supplements the Post-COVID-19 Functional Status (PCFS) scale, designed to assess the functional status of patients previously infected with the SARS-CoV-2 virus, with an assessment of a patient's current personal health and lifestyle habits, including stress management, diet, exercise, tobacco use, and alcohol consumption.
“Since inception QHSLab has been focused on the vast primary care market, which accounts for 52% of all healthcare utilization in the U.S. PCP’s are looking to companies like QHSLab to assist them in reducing non-clinical administrative burdens and increase practice revenue, enabling them to focus on patient care and satisfaction. Our latest Post-COVID-19 Health Habits Assessment is another way that QHSLab is accomplishing this goal for our medical practice clients,” concluded Grogan.
Medicare and commercial payor reimbursement rates for non-face-to-face services such as QHSLab’s Post-COVID-19 Health Habits Assessment pay PCPs approximately $100 per encounter. QHSLab has launched four core digital health assessments over the past 12 months, covering 100% of patients that see their PCP at any given time. These assessments include mental health evaluation (stress, anxiety, depression, sleep issues, and pain), allergies and asthma, medical nutrition, and post-COVID conditions.
Recent internal data suggests that QHSLab physician clients are generating new revenues in excess of $80-100,000 per year from these additional services, and the Company is just beginning to achieve the validated business model projections of licensing its digital health technology and providing administrative services under contract to its physician client base. Management at QHSLab, Inc. (USAQ) strongly believes that the Company’s current stock price is not reflective of the Company's true value, its sound fundamental point-of-care and digital healthcare business, near-term prospects, or addressable market opportunities.
For more information, please visit www.qhslab.com.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patients responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving the revenues of their practice.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/USAQcorp
TommyBoyTrader9460
2 years ago
$USAQ News out! Expecting a strong open here…
QHSLab Announces New Strategic Alliance with Medical License Factory For its AllergiEnd® Products and Services
Press Release | 06/24/2022
This Partnership Expands QHSLab’s Independent Practitioner Network, While Addressing Current Industry Pain Points.
WEST PALM BEACH, FL, June 24, 2022 (GLOBE NEWSWIRE) -- QHSLab, Inc. (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging point of care technologies, today announced a strategic alliance with Medical License Factory, LLC, a prominent physician licensing and management services organization, for its AllergiEnd® allergy diagnostic and allergen immunotherapy products and clinical decision support digital health services. Medical License Factory will facilitate working relationships between QHSLab and Medical License Factory’s network of physicians, while providing administrative, medical billing, recruitment services, marketing, and promotional support for the new alliance.
“Today’s announcement is further evidence of our continued progress and momentum as we expand our independent medical provider practice network. The growing adoption of AllergiEnd®’s allergy diagnostic services and allergen immunotherapy products reflects the attractiveness of our patient-centered tools and income-producing services for medical practices. Our services proactively address chronic diseases, provide preventive care, and enable the broad market of general practitioner physicians to expand their practices and reimbursement base, especially in times of rising interest rates, inflation, and labor costs,” said Troy Grogan, CEO of QHSLab.
QHSLab and Medical License Factory share common goals and complementary methods of supporting physicians with services needed to improve clinical outcomes, streamline practice operations, increase practice revenue, and provide cost-effective solutions. Medical License Factory has over ten years of experience in various critical practice-management modalities, including medical licensing, recruiting, quality assurance, medical billing, human resources, and healthcare marketing support.
Recent financial headlines have many concerned - physicians included. It's easily forgotten that many physicians are business owners, burdened by clinical cases and the stressors of running a small business. QHSLab offers physicians an ongoing revenue stream with high-demand services that will continue to be clinical needs, despite turbulence in the financial markets. Together with Medical License Factory, QHSLab will help small medical practices overcome inflation, rising interest rates, business costs, and the healthcare labor shortage.
“We are very excited to be partnering with QHSLab, which will enhance our working relationship with our network of independent medical practices while allowing us to introduce our services to current QHSLab physicians. The AllergiEnd® allergy diagnostic and allergen immunotherapy products are highly needed additions to the primary care practice, that benefit our physician clients and their patients, while adding a new income stream to the practice,” said Lilia Waldero, President of Medical License Factory.
"Discovering a corporate partner like Medical License Factory that genuinely enhances, compliments, and expands existing service offerings is a rare and exciting next step in today's healthcare industry," continues Troy Grogan. "As an early-stage, publicly-traded company, we believe that the future of medicine is meant to be shared, especially with the physicians who utilize our products and services and with the forward-thinking investors who invest in the future of medicine. Growth through these types of partnerships strengthens our position, allowing intelligent investors to beat Wall Street while securing their position in the digital healthcare market."
For more information, please visit QHSLab at www.usaqcorp.com and Medical License Factory here https://licenciasmedica.com/
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess their patients’ responses quickly and effectively using advanced artificial intelligence. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving the revenues of their practice.
About Medical License Factory, LLC.
Medical License Factory has over 10 years of experience in Medical Licensing, Recruiting, Quality Assurance, Medical Billing, Human Resources, and Marketing. It has extensive experience in guiding foreign-graduate doctors through the process of obtaining a medical license and beginning to practice within the United States. In addition to helping clients obtain their licenses, it supports its clients in various aspects of their practices, including quality assurance, medical billing, human resources, healthcare marketing and documentation of interest such as: registration of medical practices, Medicaid, Medicare, narcotics licenses, DEA, renewals, verification of credentials, among others.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/USAQcorp
News
Market Data
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
toddski
4 months ago
Screech691
2 years ago
dealerschool2006
3 years ago
Renee
3 years ago
lucky__stock
3 years ago
SpaceManTrades
3 years ago
StockHighAlert-
3 years ago
